Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/120231
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fernández de Misa, Ricardo | - |
dc.contributor.author | Hernández Machín, B. | - |
dc.contributor.author | Servitje Bedate, Octavio | - |
dc.contributor.author | Valentí Medina, Francesc | - |
dc.contributor.author | Maroñas Jiménez, L. | - |
dc.contributor.author | Ortiz Romero, Pablo L. | - |
dc.contributor.author | Sánchez Schmidt, Júlia | - |
dc.contributor.author | Pujol, Ramon M. | - |
dc.contributor.author | Gallardo, F. (Fernando) | - |
dc.contributor.author | Pau Charles, I. | - |
dc.contributor.author | Garcia-Muret, Maria P. | - |
dc.contributor.author | Pérez Gala, S. | - |
dc.contributor.author | Román, Concepción | - |
dc.contributor.author | Cañueto, J. | - |
dc.contributor.author | Blanch Rius, L. | - |
dc.contributor.author | Izu, Rosa | - |
dc.contributor.author | Ortiz Brugués, Ariadna | - |
dc.contributor.author | Martí, Rosa M. | - |
dc.contributor.author | Blanes, M. | - |
dc.contributor.author | Morillo, Mercedes | - |
dc.contributor.author | Sánchez, P. | - |
dc.contributor.author | Peñate, Yerai | - |
dc.contributor.author | Bastida, J. | - |
dc.contributor.author | Pérez Gil, Amalia | - |
dc.contributor.author | Lopez Lerma, Ingrid | - |
dc.contributor.author | Muniesa Montserrat, Cristina | - |
dc.contributor.author | Estrach Panella, Ma. Teresa (María Teresa) | - |
dc.date.accessioned | 2018-02-26T09:33:56Z | - |
dc.date.available | 2018-10-10T05:10:20Z | - |
dc.date.issued | 2018-03 | - |
dc.identifier.issn | 0307-6938 | - |
dc.identifier.uri | http://hdl.handle.net/2445/120231 | - |
dc.description.abstract | Background: Data regarding response to treatment in lymphomatoid papulosis (LyP) are scarce. Aim: To assess the daily clinical practice approach to LyP and the response to first-line treatments. Methods: This was a retrospective study enrolling 252 patients with LyP. Results: Topical steroids, methotrexate and phototherapy were the most common first-line treatments, prescribed for 35%, 20% and 14% of the patients, respectively. Complete response (CR) was achieved in 48% of treated patients. Eczematous lesions significantly increased relative risk (RR) of not achieving CR (RR = 1.76; 95% CI 1.16-2.11). Overall median time to CR was 10 months (95% CI 6-13 months), and 78% of complete responders showed cutaneous relapse; both results were similar for all treatment groups (P > 0.05). Overall estimated median disease-free survival (DFS) was 11 months (95% CI 9-13 months) but DFS for patients treated with phototherapy was 23 months (95% CI 10-36 months; P < 0.03). Having the Type A LyP variant (RR = 2.04; 95% CI 0.96-4.30) and receiving a first-line treatment other than phototherapy (RR = 5.33; 95% CI 0.84-33.89) were significantly associated with cutaneous early relapse. Of the 252 patients, 31 (13%) had associated mycosis fungoides unrelated to therapeutic approach, type of LyP or T-cell receptor clonality. Conclusions: Current epidemiological, clinical and pathological data support previous results. Topical steroids, phototherapy and methotrexate are the most frequently prescribed first-line treatments. Although CR and cutaneous relapse rates do not differ between them, phototherapy achieves a longer DFS. Presence of Type A LyP and use of topical steroid or methotrexate were associated with an increased risk of early relapse. | - |
dc.format.extent | 7 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Wiley | - |
dc.relation.isformatof | Versió postprint del document publicat a: https://doi.org/10.1111/ced.13256. | - |
dc.relation.ispartof | Clinical and Experimental Dermatology, 2018, vol. 43, num. 2, p. 137-143 | - |
dc.relation.uri | https://doi.org/10.1111/ced.13256 | - |
dc.rights | (c) British Association of Dermatologists, 2017 | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Limfomes | - |
dc.subject.classification | Malalties de la pell | - |
dc.subject.classification | Fototeràpia | - |
dc.subject.other | Lymphomas | - |
dc.subject.other | Skin diseases | - |
dc.subject.other | Phototherapy | - |
dc.title | First-line treatment in lymphomatoid papulosis: a retrospective multicentre study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.identifier.idgrec | 674076 | - |
dc.date.updated | 2018-02-26T09:33:56Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 28994134 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Medicina) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
674076.pdf | 221.46 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.